We receive royalties on a number of marketed products that utilize our proprietary PEGylation platform. PEGINTRON®, Macugen®, and CIMZIA®are the most significant of these products with PEGINTRON being the largest source of our royalty income. We also receive royalties related to certain sales of Oncaspar and Adagen. These products were developed by us using PEGylation and were sold in January to Sigma-Tau Pharmaceuticals, Inc. as part of the divestiture of our Specialty Pharmaceutical operations.
PEGINTRON is a PEG-enhanced version of Merck’s alpha interferon product, INTRON® A, which is used both as a monotherapy and in combination with REBETOL® (ribavirin) capsules for the treatment of chronic hepatitis C. Sylatron is approved for the adjuvant treatment of melanoma
Macugen (pegaptanib sodium injection) is currently being marketed by Valeant and Pfizer for the treatment of neovascular (wet) age-related macular degeneration, an eye disease associated with aging that destroys central vision.
CIMZIA was approved in April 2008 for the treatment of Crohn’s disease and adult patients suffering from moderate to severe rheumatoid arthritis and is marketed by UCB.
As part of the sales agreement with Sigma-Tau, we receive royalties on incremental sales above a 2009 baseline amount from what had been Enzon’s four marketed products, including Oncaspar and Adagen. Oncaspar is an oncology product for treatment of patients with acute lymphoblastic leukemia and Adagen is for the treatment of combined immunodeficiency disease.